Ocumension Therapeutics (FRA:5DG) Total Stockholders Equity : €375.01 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics Total Stockholders Equity?

Ocumension Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €375.01 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Ocumension Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was €0.54. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Ocumension Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.05.

Ocumension Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Ocumension Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics Total Stockholders Equity Chart

Ocumension Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

-265.43

314.55

431.87

372.18

375.01

Ocumension Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial						431.87	417.22	372.18	353.89	375.01

Ocumension Therapeutics (FRA:5DG) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Ocumension Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(375.005	-	0)	/	690.904
	=	0.54

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Ocumension Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(16.994	+	0.727)	/	375.005
	=	0.05

Ocumension Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics (FRA:5DG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (FRA:5DG) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

01477:Hong Kong

Address

No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN

Website

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Ocumension Therapeutics (FRA:5DG) Headlines

No Headlines